Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all synonyms
High levels of TRAIL-R3 and CCR-2 expression in tumor epithelial cells identified patients with early breast cancer with poor outcomes.
Results identified epigenetic inactivation of TNFRSF10C and TNFRSF10D (show TNFRSF10D Proteins) in majority of cervical cancer cases.
DcR1 levels in serum sample which were significantly lower in AMD (show AMD1 Proteins) patients.
DcR1 upregulation mediates temozolomide resistance.
The membrane expression of the TRAIL receptors DR4 (show HLADRB4 Proteins), DR5 (show TNFRSF10B Proteins), DcR1 and DcR2 (show CCR6 Proteins) is greater in normal endometrium than endometrioid adenocarcinoma (EAC (show CYLD Proteins)). The level of the receptors in EAC (show CYLD Proteins) is not dependent on grading and staging and does not predict survival.
the results presented here claim for a relevant impact of aberrant methylation of decoy receptors in melanoma and allow to understand how the silencing of DcR1 and DcR2 (show CCR6 Proteins) is related to melanomagenesis.
GATA4 (show GATA4 Proteins) and DcR1 promoter hypermethylation is tumor specific event in glioblastoma but they promoter methylation cannot be considered as a prognostic marker of glioblastoma survival.
Primary EOC is associated to a lower TRAIL-R3 expression.
Data show that about 20% of AML (show RUNX1 Proteins) patients highly expressed decoy receptor TRAIL-R3, which was strongly correlated to a shortened overall survival.
Decoy receptors DcR1 and DcR2 (show CCR6 Proteins) on CD8 (show CD8A Proteins)+ T cells, but not on CD4 (show CD4 Proteins)-positive T cells, are positively correlated with patients' DAS (show ube3a Proteins) scores.
The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor contains an extracellular TRAIL-binding domain and a transmembrane domain, but no cytoplasmic death domain. This receptor is not capable of inducing apoptosis, and is thought to function as an antagonistic receptor that protects cells from TRAIL-induced apoptosis. This gene was found to be a p53-regulated DNA damage-inducible gene. The expression of this gene was detected in many normal tissues but not in most cancer cell lines, which may explain the specific sensitivity of cancer cells to the apoptosis-inducing activity of TRAIL.
TNF-related apoptosis-inducing ligand receptor 3
, antagonist decoy receptor for TRAIL/Apo-2L
, cytotoxic TRAIL receptor-3
, decoy TRAIL receptor without death domain
, decoy receptor 1
, lymphocyte inhibitor of TRAIL
, tumor necrosis factor receptor superfamily member 10C
, tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain